Neurocrine Biosciences advertising spend, FY2025

Neurocrine Biosciences (NBIX) reported $227M of advertising expense for the fiscal year ended Dec 31, 2025. That is 7.9% of revenue of $2.9B. Up 18.7% from FY2024.

Ad spend, FY2025
$227M
year ended Dec 31, 2025
Change vs prior year
+18.7%
vs FY2024
Share of revenue
7.9%
of $2.9B revenue
Rank by ad spend
#212
of 458 companies

Key facts

  • Ad spend is 3.5x its FY2020 level ($64.8M), faster than revenue (2.7x).
  • FY2025 is the highest year on file, going back to FY2018.
  • Largest increase +115.7% in FY2021.
  • Ad spend has risen 7 years in a row.
  • Ad spend is 7.9% of revenue, up from 6.2% in FY2020.
  • Neurocrine Biosciences spends more on advertising than 54% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 1.7x the median of 4.5%.

Ad spend by fiscal year

$0 $100M $200M $300M FY2018 (ended 2018-12-31): $20.5M 2018 FY2019 (ended 2019-12-31): $40.6M 2019 FY2020 (ended 2020-12-31): $64.8M 2020 FY2021 (ended 2021-12-31): $140M 2021 FY2022 (ended 2022-12-31): $150M 2022 FY2023 (ended 2023-12-31): $160M 2023 FY2024 (ended 2024-12-31): $191M 2024 FY2025 (ended 2025-12-31): $227M 2025 $227M

Ad spend as % of revenue

0% 5% 10% 15% FY2018 (ended 2018-12-31): 4.5% 2018 FY2019 (ended 2019-12-31): 5.2% 2019 FY2020 (ended 2020-12-31): 6.2% 2020 FY2021 (ended 2021-12-31): 12.3% 2021 FY2022 (ended 2022-12-31): 10.1% 2022 FY2023 (ended 2023-12-31): 8.5% 2023 FY2024 (ended 2024-12-31): 8.1% 2024 FY2025 (ended 2025-12-31): 7.9% 2025 7.9%

Ad spend in context, FY2025

Advertising was 19.6% of selling, general and administrative expense. Research and development spending was 4.5x advertising. Advertising equalled 36.6% of operating income.

Advertising $227M AdvertisingExpense
Selling, general and administrative $1.2B ad spend = 19.6%
Research and development $1B R&D = 4.5x ad spend
Operating income $619M ad spend = 36.6%
Net income $479M

Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.

History

Download CSV
Fiscal year Period end Ad spend YoY Revenue Ad / revenue Tag Filing
FY2025 Dec 31, 2025 $227M +18.7% $2.9B 7.9% AdvertisingExpense 10-K Feb 11, 2026
FY2024 Dec 31, 2024 $191M +19.4% $2.4B 8.1% AdvertisingExpense 10-K Feb 11, 2026
FY2023 Dec 31, 2023 $160M +6.8% $1.9B 8.5% AdvertisingExpense 10-K Feb 11, 2026
FY2022 Dec 31, 2022 $150M +7.1% $1.5B 10.1% AdvertisingExpense 10-K Feb 10, 2025
FY2021 Dec 31, 2021 $140M +115.7% $1.1B 12.3% AdvertisingExpense 10-K Feb 9, 2024
FY2020 Dec 31, 2020 $64.8M +59.6% $1B 6.2% AdvertisingExpense 10-K Feb 9, 2023
FY2019 Dec 31, 2019 $40.6M +98.0% $788M 5.2% AdvertisingExpense 10-K Feb 11, 2022
FY2018 Dec 31, 2018 $20.5M n/a $451M 4.5% AdvertisingExpense 10-K Feb 5, 2021

Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.

What the figure is

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Compared with similar spenders

The 6 companies closest to Neurocrine Biosciences in latest-year ad spend.

Rank Company Ad spend Ad / revenue YoY Fiscal year
209 Hertz Global $230M 2.7% -12.9% FY2025
210 Grand Canyon Education $229M 20.7% +7.9% FY2025
211 Garmin $229M 3.2% +19.3% FY2025
212 Neurocrine Biosciences $227M 7.9% +18.7% FY2025
213 McCormick $225M 3.3% +2.9% FY2025
214 Peloton Interactive $224M 9.2% -9.2% FY2026
215 Dexcom $224M 4.8% +15.2% FY2025

Full ranking of 458 companies · Biggest increases #120 · Up 5+ years in a row #22

Questions

How much does Neurocrine Biosciences spend on advertising?

Neurocrine Biosciences spent $227M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 11, 2026.

What percentage of revenue does Neurocrine Biosciences spend on advertising?

7.9% of revenue in fiscal 2025 ($227M against $2.9B). The median across the 458 companies tracked is 4.5%.

Is Neurocrine Biosciences spending more on advertising?

Yes. Ad spend rose 18.7% in fiscal 2025 from fiscal 2024. It has risen 7 years in a row.

How does Neurocrine Biosciences rank by advertising spend?

#212 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.

Does Neurocrine Biosciences spend more on advertising than on R&D?

No. In fiscal 2025 it spent $1B on research and development and $227M on advertising.

What does Neurocrine Biosciences's advertising figure include?

Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).

Company and source

Filing
10-K for FY2025, filed Feb 11, 2026
Accession number
0000914475-26-000007
Company
NEUROCRINE BIOSCIENCES INC, CIK 914475, SIC 2836 (Biological Products, (No Diagnostic Substances))
Headquarters
San Diego, CA
Incorporated in
DE
Fiscal year ends
December 31
Listed on
Nasdaq
SEC filer status
Large accelerated filer
Data
SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
Cite
Neurocrine Biosciences advertising spend, FY2018-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 11, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/neurocrine-biosciences/advertising-spend/
Download
CSV, all years · CSV, all 458 companies